| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.08 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.33 | 0.08 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.11 | 0.08 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.08 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.08 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.27 | 0.08 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.08 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.08 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.3 | 0.09 |